Nataly Tarasenko

Felsenstein Medical Research Center

Affiliated withFelsenstein Medical Research Center Davidoff Center, Rabin Medical Center

Research Area

Cancer Research

Biography

Nataly Tarasenko has not added Biography.
If you are Nataly Tarasenko and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 2	2022

Other Publications

Article	Year
The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Investigational new drugs\| PubMed ID: 16502348	2006
Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Clinical & experimental metastasis\| PubMed ID: 18506586	2008
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. Journal of medicinal chemistry\| PubMed ID: 19378992	2009
The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity. Investigational new drugs\| PubMed ID: 20862515	2012
Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor. PloS one\| PubMed ID: 22384017	2012
A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo. Biochemical pharmacology\| PubMed ID: 24463168	2014
The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin. PloS one\| PubMed ID: 26752418	2016
Bi-functional prodrugs of 5-aminolevulinic acid and butyric acid increase erythropoiesis in anemic mice in an erythropoietin-independent manner. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences\| PubMed ID: 27283485	2016
Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft. Investigational new drugs\| PubMed ID: 28315153	2017
AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair. Investigational new drugs\| PubMed ID: 28884410	2018
Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors. Journal of cellular biochemistry\| PubMed ID: 29135083	2018
The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model. International journal of molecular sciences\| PubMed ID: 30736437	2019
Valproic Acid Prodrug Affects Selective Markers, Augments Doxorubicin Anticancer Activity and Attenuates Its Toxicity in a Murine Model of Aggressive Breast Cancer. Pharmaceuticals (Basel, Switzerland)\| PubMed ID: 34959644	2021
Palbociclib in combination with sunitinib exerts a synergistic anti-cancer effect in patient-derived xenograft models of various human cancers types. Cancer letters\| PubMed ID: 35358627	2022